Recent Company News

• 07:13 AM ET Jun 02, 2025
  

  Lyra Therapeutics reports results from ENLIGHTEN 2 Phase 3 trial of LYR-210 in the treatment of chronic rhinosinusitis (CRS) ($4.93, 0.00)

• 02:13 AM ET May 05, 2025
  

  Nanobiotix presents full results from the completed Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer (€3.05, 0.00)

• 08:33 AM ET Apr 22, 2025
  

  Tarsus Pharmaceuticals to present four data sets at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting ($48.51, 0.00)

• 09:24 PM ET Apr 17, 2025
  

  FDA updates label for Bristol Myers Squibb's CAMZYOS ($49.23, 0.00)

• 04:17 PM ET Apr 14, 2025
  

  Bristol Myers Squibb Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for adult patients with symptomatic NYHA class II-III non-obstructive hypertrophic cardiomyopathy (nHCM) did not meet its dual primary endpoints ($51.34, 0.00)

• 02:33 AM ET Jan 21, 2025
  

  Nanobiotix doses first patient in new randomized Phase 2 study evaluating JNJ-1900 (NBTXR3) for patients with stage 3 unresectable Non-Small Cell Lung cancer (€3.04, 0.00)

• 04:01 AM ET Dec 16, 2024
  

  NMPA accepts submission of Grand Pharmaceutical Group's NDA for TP-03 for Demodex blepharitis (HK$4.67, 0.00)

• 04:16 PM ET Dec 09, 2024
  

  Nanobiotix announces completion of phase 1 study of NBTXR3 (JNJ-1900) in pancreatic cancer

• 07:10 AM ET Oct 15, 2024
  

  Lyra Therapeutics fully enrolls pivotal Phase 3 ENLIGHTEN 2 trial of LYR-210 for the treatment of chronic rhinosinusitis ($0.22, 0.00)

• 04:56 AM ET Sep 01, 2024
  

  Bristol Myers Squibb presents new long-term follow-up results from MAVA-LTE study of CAMZYOS ($49.95, 0.00)